Global Lower Respiratory Tract Infection Treatment Market, By Mode of Transmission (Hospital Acquired, Ventilator Acquired, Community Acquired), Treatment (Medication, Intravenous Fluids, Humidified Oxygen, Vaccines), Route of Administration (Oral, Parenteral, Others), Type of Infection (Pneumonia, Bronchitis, Influenza, Tuberculosis, Others), Diagnosis (Mucus Samples, Blood Tests, Chest X-rays, Pulse Oximetry), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Lower Respiratory Tract Infection Treatment Market Analysis and Size
Pneumonia is a term that is frequently used to describe lower respiratory tract sickness. The flu, bronchitis, bronchiolitis, and pneumonia are some of the most prevalent ailments, although they are not all categorized similarly. Around the world, lower respiratory tract infections are the leading cause of sickness and death in children and adults. For the treatment of critically ill patients with acute respiratory distress syndrome, novel lung treatments are being explored by numerous research institutions (ARDS).
Data Bridge Market Research analyses that the lower respiratory tract infection treatment market, which was USD 50.22 billion in 2022, is expected to reach USD 89.57 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lower Respiratory Tract Infection Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Mode of Transmission (Hospital Acquired, Ventilator Acquired, Community Acquired), Treatment (Medication, Intravenous Fluids, Humidified Oxygen, Vaccines), Route of Administration (Oral, Parenteral, Others), Type of Infection (Pneumonia, Bronchitis, Influenza, Tuberculosis, Others), Diagnosis (Mucus Samples, Blood Tests, Chest X-rays, Pulse Oximetry), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), Hikma Pharmaceuticals PLC (U.K.), Allergan (Ireland), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Lupin (India), SHIONOGI & Co., Ltd. (Japan), AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Infections that affect the airways (below the level of the larynx), such as the trachea and alveolar sacs, are referred to as lower respiratory tract infections (LRTI). LRTI can be categorized in several different ways. While pneumonia is an example of a severe infection that damages the alveolar sacs, severe infections that impact the airways include acute bronchitis, bronchiolitis, and the flu.
Lower Respiratory Tract Infection Treatment Market Dynamics
Drivers
- The rising prevalence of chronic respiratory disorders will drive the growth of the market
The rising prevalence of chronic respiratory disorders such as asthma, chronic pulmonary fibrosis, pulmonary hypertension, and occupational lung disease drive the respiratory tract infection market forward. For example, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyperresponsiveness. These are certain factors that will propel the market growth.
- The rise in the geriatric population will drive the market growth
The market's rise is anticipated to be aided by the growing geriatric population during the projection period of 2023-2030. The World Health Organization (WHO) projects that by 2050, there will be approximately 2 billion geriatric people globally, up from an estimated 524 million in 2010. Geriatrics are more likely to have lower respiratory tract infections because of their weakened immune systems, which is predicted to increase the market's growth rate.
Opportunities
- Collaborations and partnerships will act as an opportunity
Numerous organizations, institutions, and agencies are working together to enhance diagnostic and medical care to minimize the burden of respiratory illnesses on people worldwide. For instance, to fight chronic respiratory disorders, the World Health Organization (WHO) encouraged the creation of the Global Alliance against Chronic Respiratory Diseases (GARD). The primary objectives of GARD are to create simple and economic chronic respiratory disease (CRD) solutions and to persuade nations to undertake CRD prevention and health promotion measures. These are the certain reasons which will boost the market expansion.
Restraints/Challenges
- Side-effects associated with lower respiratory tract infection treatment
Overprescribing antibiotics is associated with a higher risk of adverse effects, frequent follow-up appointments, and a greater medicalization of self-limiting illnesses. Overprescribing antibiotics is a significant problem in primary care since viruses frequently cause infections. Almost 90% of all antibiotic prescriptions issued by general practitioners are for respiratory system infections.
This lower respiratory tract infection treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lower respiratory tract infection treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2021, Biapenem was approved by the FDA for the treatment of intra-abdominal, lower respiratory, and severe urinary tract infections. Biapenem is typically given to patients with severe urinary tract infections, lower respiratory infections, or intra-abdominal infections. It's a parenterally administered carbapenem antibacterial medication. Biapen's dosage is considerably less than that of other carbapenems, though.
Global Lower Respiratory Tract Infection Treatment Market Scope
The lower respiratory tract infection treatment market is segmented on the basis of mode of transmission, type of infection, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Mode of Transmission
- Hospital Acquired
- Ventilator Acquired
- Community Acquired
Type of Infection
- Pneumonia
- Bronchitis
- Influenza
- Tuberculosis
- Others
Route of Administration
- Oral
- Parenteral
- Others
Diagnosis
- Mucus Samples
- Blood Tests
- Chest X-rays
- Pulse Oximetry
Treatment
- Medication
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Acetaminophen
- Bronchodilator inhaler
- Antibiotics
- Others
- Intravenous Fluids
- Humidified Oxygen, Vaccines
- Vaccines
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Lower Respiratory Tract Infection Treatment Market Regional Analysis/Insights
The lower respiratory tract infection treatment market is analysed and market size insights and trends are provided by country, mode of transmission, type of infection, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the lower respiratory tract infection treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the lower respiratory tract infection treatment market due to the region's growing geriatric population, immune-compromised seniors, and multi-drug resistant bacterial infections in youngsters. The presence of significant key players and rising healthcare costs will further contribute to the market's rapid expansion in this area.
Asia-Pacific is expected to grow at the highest rate from 2023 to 2030 because unhealthy lifestyles are becoming more common in this area. Expanding the healthcare infrastructure and increasing patient awareness will also boost the market's growth rate in this area.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Lower Respiratory Tract Infection Treatment Market Share Analysis
The lower respiratory tract infection treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lower respiratory tract infection treatment market.
Some of the major players operating in the lower respiratory tract infection treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Abbott (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Allergan (Ireland)
- Eli Lilly and Company (U.S.)
- Aurobindo Pharma (India)
- Lupin (India)
- SHIONOGI & Co., Ltd. (Japan)
- AbbVie Inc. (U.S.)
SKU-